Share on StockTwits

Shares of Sarepta Therapeutics (NASDAQ:SRPT) saw a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 11,921,297 shares, a drop of 10.9% from the April 15th total of 13,380,844 shares, Analyst Ratings Network reports. Currently, 34.5% of the shares of the company are short sold. Based on an average daily volume of 2,945,395 shares, the days-to-cover ratio is currently 4.0 days.

A number of analysts have recently weighed in on SRPT shares. Analysts at Deutsche Bank raised their price target on shares of Sarepta Therapeutics from $17.00 to $35.00 in a research note on Tuesday, April 22nd. They now have a “hold” rating on the stock. Separately, analysts at Citigroup Inc. upgraded shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating in a research note on Tuesday, April 22nd. Finally, analysts at Canaccord Genuity upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 21st. They now have a $63.00 price target on the stock, up previously from $27.00. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company. Sarepta Therapeutics has an average rating of “Hold” and a consensus price target of $38.72.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 31.42 on Monday. Sarepta Therapeutics has a 52 week low of $12.12 and a 52 week high of $55.61. The stock’s 50-day moving average is $30.37 and its 200-day moving average is $25.72. The company’s market cap is $1.278 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Thursday, May 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.05. The company had revenue of $6.09 million for the quarter, compared to the consensus estimate of $3.45 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. The company’s revenue for the quarter was up 36.0% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutics will post $-3.20 earnings per share for the current fiscal year.

Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.